for groups 5, 7 and 8, respectively (median event-free survival: groups 1-2: not reached; groups 3-8: 15.9, 13.5, 6.3, 16.0, 7.5 and 12.5 months (Figures 1b and c) ). Thus, the OS of AML with inv(3)(q21q26)/t(3;3)(q21;q26) was similar to complex aberrant AML. Many cytogenetic studies did not specify on outcomes of AML with inv(3)(q21q26)/t(3;3)(q21;q26), but combined this subtype with other rare or unfavorable alterations. According to a recent Medical Research Council (MRC) study, the 10-year OS rate was 3% and the cumulative incidence of relapse was 89% in patients with AML and inv(3)(q21q26)/t(3;3)(q21;q26), 4 and Lugthart et al.
Recently, we characterized 81 cases according to cytogenetics and mutations in seven candidate genes, detecting an overall mutation rate of 72.8%. 1 The most frequent genetic abnormalities detected using a sensitive next-generation amplicon deep-sequencing method were found in TET2 2 with aberrations also seen in CBL, RUNX1 and RAS.
1 In this study, we aimed to further characterize this defined cohort of CMML patients by studying five additional genes: IDH1, IDH2, 3,4 NPM1, ASXL1 and EZH2. [5] [6] [7] Mutations in NPM1 have been described in 6% (6/97) of CMML patients and were associated with a poor prognosis.
8 ASXL1 belongs to the enhancer of trithorax and polycomb gene family and is mutated in 33% of CMML. 9 Of special interest in our study was EZH2, that localizes to chromosome 7q36, proposed to function as an oncogene or a tumor suppressor gene in different diseases. [5] [6] [7] EZH2 encodes the catalytic subunit of the polycomb repressive complex 2, a highly conserved histone H3 lysine 27 methyltransferase that influences stem cell renewal by epigenetic modification. 6, 7 As reported by Ernst et al. 6 EZH2 mutations were identified in 13% of CMML patients and myelodysplastic/ myeloproliferative neoplasm patients mutated in EZH2 had been associated with an inferior outcome (P ¼ 0.0006). We aimed to identify the prevalence of mutations in CMML, identify any associations between them, as well as their correlation with morphology, cytogenetics and survival.
As initially presented elsewhere, 81 patients with CMML-1 (n ¼ 45) or CMML-2 (n ¼ 36) were collected and investigated (Supplementary Information 1). 1 The study design adhered to the tenets of the Declaration of Helsinki and was approved by our institutional review board before its initiation. We applied nextgeneration amplicon deep-sequencing using the small volume Titanium assay (454 Life Sciences, Branford, CT, USA). A sequencing library was prepared for hotspot regions of IDH1 (exon 4), IDH2 (exon 4), NPM1 (exon 11) and the complete coding region of EZH2 (Supplementary Table 1) , comprising a total of 22 amplicons with a median size of 336 bp. All samples were barcode-tagged using 48.48 Access Array technology (Fluidigm, South San Francisco, CA, USA), starting with 50 ng genomic DNA per sample (PCR amplification protocol, Supplementary Table 2 ). Tagged next-generation amplicon deep-sequencing primer sequences are available online (Supplementary Table 3 ). Next-generation amplicon deep-sequencing data were analyzed using Sequence Pilot version 3.4 (JSI Medical Systems, Kippenheim, Germany). The hotspot region of ASXL1 exon 12 (n ¼ 6 amplicons) was investigated by conventional Sanger sequencing using primer sequences as published by Gelsi-Boyer et al. 9 Statistical analyses were performed using SPSS version 14.0.1 (SPSS Inc., Chicago, IL, USA). Reported P-values are two-sided and not corrected for multiple testing.
The target genes (in total, 1782 amplicons) were successfully analyzed in all cases. A median of 498 reads per amplicon (range 162-740) were obtained for IDH1, IDH2, NPM1 and EZH2, thus yielding a sufficient coverage for mutation detection with high sensitivity. Overall, in this cohort of 81 CMML patients 32 variants (17 different) were detected in 13/81 cases (16.0%) for these four genes. After excluding 7 polymorphisms and 9 silent mutations, 13 different aberrations (Supplementary  Table 4) were detected in IDH1 (1/81; 1.2%), IDH2 (3/81; 3.7%), NPM1 (1/81; 1.2%) and EZH2 (9/81; 11.1%). Summarizing this data and taking our previously published data into account we were able to detect at least one molecular mutation in 61/81 (75.3%) patients (Figure 1a ).
Another gene recently described to be mutated in clonal hematological diseases is ASXL1 on chromosome 20q11.1. 9 Therefore, we investigated ASXL1 exon 12 mutations in 79/81 cases (no DNA available in two cases). In all, 27 of these 79 cases (34.2%) harbored a mutation in ASXL1, not including 14 cases that harbored the putative c.1934dupG germline variant. 10 Of note, thus far, we sequenced 463 cases of various myeloid malignancies and detected the corresponding putative ASXL1 mutation 1900_1922del (Glu635ArgfsX16) in 21 patients overall (Supplementary Table 4 ). In particular, 11/21 alterations were observed in this CMML cohort. Overall, in our cohort of 81 cases, only 15 (18.5%) remained in which no mutation was detectable. Therefore, as shown in Figure 1a , in total 81.5% of cases harbored at least one molecular aberration (range: 1-7) with a median of two genes being mutated (range: 1-5).
In more detail, we observed 10 novel different EZH2 mutations in nine patients: 6 missense, 3 frameshifts (2 deletions, 1 insertion) and 1 splice mutation (Supplementary Table 4 ). Two of the nine affected patients concomitantly harbored two different EZH2 mutations, however, these were located on two separate amplicons not allowing to discriminate between a mono-or biallelic state. EZH2 mutations were spread over several exons, but predominantly were located in the four conserved regions and, in particular, 6/10 mutations were located in the conserved catalytic SET (enhancer of zeste and trithorax) domain (amino acids 618-751), essential for the methyltransferase activity of EZH2 (Supplementary Table 4 Letters to the Editor note, no case revealed the Tyr641 mutation as described in follicular and diffuse large B-cell lymphomas of germinal center origin suggesting a different oncogenic mechanism in these diseases. 11 In our cohort, we detected one case with a homozygous mutation pattern, in detail, a splice mutation before exon 17. Whether this pattern is due to an acquired uniparental disomy 7q as described as common abnormality in the literature for myelodysplastic/myeloproliferative neoplasm is not known. 6, 7 In median, the burden of EZH2 mutations was 45% of bidirectional sequencing reads (range: 1.4-88%) per patient. A similar high mutation burden was also detected in RUNX1 (median 46.7%), TET2 (median 44.6%) and CBL (median 42.5%), whereas the burden was low in RAS pathway alterations, that is, NRAS (median 11.1%), KRAS (median 27%) or JAK2 V617F mutations (median 6.9%). With respect to ASXL1 mutations, Sanger sequencing indicated a burden of B50%.
We next investigated associations of distinct mutations, however, no specific pattern was observed, that is, EZH2 mutations were detected in combination with TET2 alterations (4/10), ASXL1 (3/10), RUNX1 (3/10), CBL (2/10), JAK2 (2/10), NRAS (2/10), KRAS (1/10) and IDH2 (1/10), respectively ( Figure 1a) . Also, EZH2 and ASXL1 mutations were neither associated with CMML subtype, dysplastic/myeloproliferative characteristics, age, karyotype, white blood cell count, platelets count, hemoglobin or gender (Supplementary Information 2) .
However, with respect to the clinical data, a poor outcome was observed for patients that carried EZH2 mutations compared with EZH2 wild-type cases (alive at 3 years: 33.3 versus 69.9%; P ¼ 0.001) as shown in Figure 1b . Considering the CMML-1 and CMML-2 category (Supplementary Figure 1) , a significant prognostic difference was detectable for CMML-2 (P ¼ 0.009) but not more for CMML-1 (P ¼ 0.063). Yet, due to the limited number of EZH2-mutated cases, we did not separate the cohort into these two categories in subsequent analyses. No difference in clinical outcome was seen for ASXL1-mutated patients versus ASXL1 wild-type or taking different numbers of mutations into account.
Furthermore, we performed a survival analysis taking both EZH2 and TET2 mutations into account, as TET2-mutated patients showed a better survival in our first analysis (Figure 1c) . 1 Four patients, which concomitantly harbored an EZH2 and TET2 mutation, were added into the EZH2-mutated group, as EZH2 mutations are believed to be an early event in the disease process and precede the sequential acquisition of TET2 mutations and because EZH2 mutations remained significant in the multivariate analyses in contrast to TET2 (Supplementary Information 2) . 6 In this analysis, the cohort was significantly separated into three prognostic risk groups, that is, at 3 years 33.9% of EZH2-mutated patients, 49.7% of EZH2/ TET2 wild-type patients and 89.8% of TET2-mutated cases were alive (Po0.001). Of note, for the most frequently mutated genes, that is, EZH2, ASXL1, TET2, RAS and CBL various pairwise analyses were performed between wild-type/wild-type, mutated/wild-type, wild-type/mutated and mutated/mutated combinations. The investigations revealed no further significant associations, with the exception of EZH2-mutated versus EZH2 wild-type cases (Supplementary Table 5 ).
In conclusion, our study revealed mutations in 66/81 (81.5%) CMML patients providing new insights into the molecular heterogeneity of this disease. Besides alterations in TET2, CBL, ASXL1 and the RAS pathway, EZH2 is targeted by various types of frameshift and point mutations. EZH2 mutations constitute a novel poor prognostic risk group and, moreover, had the strongest clinical impact of all markers analyzed thus far. We suggest, therefore, that EZH2 mutational status should be taken into account in future clinical studies of CMML. 
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